AstraZeneca to acquire Neogene for up to $320m

pharmafile | November 29, 2022 | News story | Sales and Marketing  

AstraZeneca has announced that it is planning to buy Neogene for up to $320m. Biotechnology group Neogene has a focus in clinical-stage discovery and development of novel cancer therapies, and AstraZeneca plans to use this acquisition to advance its research in oncology cell therapies.

Currently, Neogene has a focus on discovering, developing and manufacturing new T cell receptor therapies (TCR-Ts), providing novel cell therapy treatments for fighting cancer.

AstraZeneca will pay $200m immediately upon closing, with the opportunity for further payments up to $120m in both contingent milestones-based and non-contingent consideration. The acquisition is expected to be finalised during the first quarter of 2023, at which point Neogene will become a wholly-owned subsidiary of AstraZeneca, although it will be based in Amsterdam and California.

Susan Galbraith, AstraZeneca’s executive vice president of Oncology R&D, commented: “This acquisition represents a unique opportunity to bring innovative science and leading experts in T cell receptor biology and cell therapy manufacturing together with our internal oncology cell therapy team, unlocking new ways to target cancer.”

She continues: “Neogene’s leading TCR discovery capabilities and extensive manufacturing experience complement the cell therapy capability we have built over the last three years, and allows us to accelerate the development of potentially curative cell therapies for the benefit of patients.”


Betsy Goodfellow

Related Content

No items found

Latest content